Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.59 |
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206459 | 0.90 | TMIGD3 (0.54) | ADORA2AADORA1ADORA2BTMIGD3TLR7 | |
| SCHEMBL2060224 | 0.89 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL7207411 | 0.89 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL7208663 | 0.88 | TMIGD3 (0.57) | ADORA2AADORA1ADORA2BTMIGD3TLR7 | |
| SCHEMBL7206499 | 0.87 | TLR7 (0.47) | ADORA2AADORA1ADORA2BTMIGD3TLR7 | |
| SCHEMBL15242319 | 0.87 | TLR7 (0.49) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL7209368 | 0.87 | TMIGD3 (0.48) | ADORA2AADORA1ADORA2BTMIGD3TLR7 | |
| SCHEMBL7209428 | 0.87 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL7206373 | 0.86 | L3MBTL1 (0.47) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL4474934 | 0.86 | TLR7 (0.62) | ADORA2AADORA1ADORA2BTMIGD3TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-9884112-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884112-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9006254-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006254-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140030344-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOSTIMULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20110027217-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110027217-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110020388-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020388-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100303850-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | SELECTA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100303850-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | SELECTA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | ADORA2A 1537/4885ADORA1 3104/4885ADORA2B 3498/4885 |
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | CD47, MSR1, CD14 | ADORA2A 1230/4885ADORA1 2149/4885ADORA2B 2113/4885 |
| US-20100303850-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | CD47, MSR1, CD14 | ADORA2A 1230/4885ADORA1 2149/4885ADORA2B 2113/4885 |
| US-20110020388-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | CD47, IFNG, TSLP | ADORA2A 1851/4885ADORA1 2873/4885ADORA2B 3458/4885 |
| US-20110027217-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | ADORA2A 1537/4885ADORA1 3104/4885ADORA2B 3498/4885 |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | ADORA2A 1537/4885ADORA1 3104/4885ADORA2B 3498/4885 |
| US-20140030344-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOSTIMULATORY AGENTS | CD47, IFNG, NFATC1 | ADORA2A 2179/4885ADORA1 3134/4885ADORA2B 3739/4885 |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | CD47, IFNG, TSLP | ADORA2A 1851/4885ADORA1 2873/4885ADORA2B 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.